Nov 11 (Reuters) – Novo Nordisk said on Wednesday it will commit $200 million to the World Diabetes Foundation over 10 years starting 2027, supporting the organization’s work to strengthen diabetes prevention and care in low- and middle-income countries.
Here are some details:
• The commitment, which lasts until 2036, will give WDF greater certainty to plan long term, build on its partnerships, and scale regional and global responses to the growing burden of diabetes, the company said
• The pledge “recognizes our work over 25 years to support people living with diabetes and related non-communicable diseases in low- and middle-income countries,” said Leif Jensen, managing director of the World Diabetes Foundation
• About 830 million people worldwide have diabetes, according to the World Health Organization
• Novo is looking to recover ground lost to US rival Eli Lilly in the diabetes and obesity drugs race, with Ozempic and Wegovy leading its charge
• Earlier this month, Novo raised its 2026 outlook for the third time this year as quarterly sales of its Wegovy pill for weight-loss beat forecasts
(Reporting by Christy Santhosh in Bengaluru; Editing by Vijay Kishore)
Comments